Paragonix Technologies Announces First Pediatric Use of LIVERguard Preservation System
2024年8月7日 - 10:11PM
ビジネスワイヤ(英語)
Leading Academic Medical Center Pioneers Donor Liver
Preservation System in Life-Saving Pediatric Transplant
Paragonix Technologies, a leading organ transplant company,
announced today the first liver transplant case in which a
pediatric donor liver was preserved using the LIVERguard® Donor
Liver Preservation System and successfully transplanted by Dr.
Deepak Vikraman at Duke University Hospital in Durham, NC. Launched
in 2022, the Paragonix LIVERguard has now been used in over 300
clinical liver transplant cases across the United States, with this
case being the first use in a pediatric setting.
The LIVERguard System has been shown in recent clinical
presentations to reduce potential post-transplant complications
compared to traditional ice storage.1 These presentations are
recent clinical reports from the GUARDIAN-LIVER global clinical
registry, a comprehensive study that seeks to evaluate a missing
piece of the organ procurement process: the impact of methods and
technologies used for liver preservation and transportation.
Additionally, the LIVERguard system has been used by liver
transplant centers across the U.S. to change the way donor livers
are procured and allocated, including long distance procurements
from Puerto Rico and Hawaii, and the enablement of OPOs to place
high-risk donor livers.
“This case exemplifies the importance of employing the latest
innovations in transplant preservation within pediatric care,” said
Dr. Vikraman, liver transplant surgeon at Duke. “New technologies
are pushing the boundaries of what was previously possible. By
advancing preservation methods, we can expand donor pools and offer
young patients a second chance at life.”
LIVERguard provides a highly controlled, state-of-the art
environment for hypothermic liver preservation, complemented by
real-time digital monitoring, to protect the donor liver throughout
the entire transplant process. Unlike traditional methods using ice
and off-the-shelf coolers, which have been the standard of care for
over 50 years, the LIVERguard represents a significant advancement
in organ transplantation technology.
“We are thrilled to see our technology utilized in the pediatric
setting, extending its impact to more liver transplant patients and
improving preservation techniques and outcomes for children,” said
Dr. Lisa Anderson, CEO and President of Paragonix Technologies.
“Partnering with a leading pediatric liver transplant center like
Duke University, whose mission it is to provide extraordinary care
aligns perfectly with our vision of improving outcomes. It is truly
exciting to work together to transform the healthcare system for
the better.”
For more information about Paragonix Advanced Organ Preservation
devices, please visit www.paragonix.com.
About Paragonix Technologies
Paragonix Technologies is a leading developer, manufacturer, and
service provider in the organ transplant industry, establishing a
novel approach to organ preservation.
Paragonix Technologies provides Advanced Organ Preservation
(“AOP”) devices that safeguard donor organs during the journey
between donor and recipient patients. Our FDA-cleared and CE-marked
devices incorporate clinically proven and medically trusted cold
preservation techniques that allow unprecedented physical and
thermal protection to the organ during transit. All Paragonix AOP
devices are natively integrated with our novel digital app,
delivering real-time organ tracking data and monitoring logistics
for transplant teams seeking a secure and centralized solution. For
more information, visit www.paragonix.com.
Follow us on Twitter: @ParagonixSherpa Connect with us on
LinkedIn: Paragonix Technologies Like Us on Facebook: Paragonix
Technologies
References
- Brubaker et al, ILTS 2024 Presentation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240807377113/en/
Media Contact: Adam Lafreniere, Sr. Director, Marketing
marketing@paragonixtechnologies.com